The patch is for people with type 1 or type 2 diabetes who require mealtime insulin.
Recent Posts
- June, 2026CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™
- CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA
- June, 2025CeQur® Marks 10 Million Mealtime Injections Replaced and Highlights Commercial Expansion
- January, 2025CeQur Closes a $120M Equity Financing to Drive Commercial Growth
- June, 2024CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management